Research has shown that HDACis and PI3K antagonists can effectively inhibit the growth of MYC-driven medulloblastoma both in vitro and in vivo, and they suggest that inhibitors of class I HDACs are effective against this type of medulloblastoma [65]. This evidence concerns the gene MYC and medulloblastoma.